Eli Lilly announced that its investigated GIP and GLP-1 inhibitor tirzepatide has demonstrated superiority over Novo Nordisk's Ozempic in a Phase III study.The SURPASS-2...
Erica Carbajal - - Wednesday 17th March 2021
Print | E-mail
The U.S. Preventive Services Task Force issued draft recommendations on March 16 to reduce the...